6月5日，Abivax S.A.盘中下跌5.49%，报99.57美元/股，成交额1.28亿美元。消息面上，公司此前公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且疗效数据位居同类研究前列，但50mg组出现前列腺癌、乳腺癌、结肠异型增生各一例，安全性争议仍未消除。
杰富瑞分析师此前指出，无论最终成因如何，癌症相关不良事件将持续压制市场情绪、影响药企战略合作空间及药物商业化前景。Wedbush Securities亦指出obefazimod面临黑框警告风险上升。该股此前盘中一度暴跌超40%后有所反弹，当前再度回落反映安全性隐忧仍在主导市场定价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.